Prognose

Kaufen	2
Halten	0
Verkaufen	0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.
Dr. Tendler oversaw 30 Major Drug Approvals, including worldwide approvals for J&J's transformational treatments in hematologic malignancies, prostate, lung and bladder cancers Dr. Tendler also oversaw 13 FDA Breakthrough Designations accelerating the early development of promising investigational medicines intended for treatment of serious oncology indications TAMPA, FL / ACCESS Newswire / March 11, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced it has appointed Craig L. Tendler, M.D.» Mehr auf accessnewswire.com
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
Live webcast fireside chat on Tuesday, March 18th at 8:30 AM PT TAMPA, FL / ACCESS Newswire / March 10, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D.» Mehr auf accessnewswire.com
TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here TAMPA, FL / ACCESS Newswire / February 19, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced it participated in the Virtual Investor "Top 5 for ‘25" On-Demand Conference . As part of the event, James Bianco, M.D.» Mehr auf accessnewswire.com

Unternehmenszahlen

Im letzten Quartal hatte TuHURA Biosciences einen Umsatz von 0,00€ und ein Nettoeinkommen von −1,94 Mio€

(EUR)	Sep. 2024	YOY
Umsatz	0,00	-
Bruttoeinkommen	0,00	-
Nettoeinkommen	−1,94 Mio	-
EBITDA	−1,97 Mio	-

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+124,12 Mio€
Anzahl Aktien	42,28 Mio
52 Wochen-Hoch/Tief	+13,26€ - +1,64€
Dividenden	Nein
Beta	0,79
KGV (PE Ratio)	−16,91
KGWV (PEG Ratio)	−0,17
KBV (PB Ratio)	+80,09
KUV (PS Ratio)	0,00

Unternehmensprofil

TuHURA Biosciences, Inc. ist ein immunonkologisches Unternehmen in der Phase 3 der Zulassungsphase und entwickelt neuartige Technologien zur Überwindung von Resistenzen gegen Krebsimmuntherapien. Der Hauptsitz des Unternehmens befindet sich in Tampa, FL.